147 results on '"De Caterina A"'
Search Results
2. Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions
3. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions
4. Do We Need Fasting Prior to Coronary Angiography? The CORO-NF Randomized Pragmatic Study
5. Inferior vena cava filters: Concept review and summary of current guidelines
6. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry
7. Adipose tissue n-3/n-6 fatty acids ratios versus n-3 fatty acids fractions as predictors of myocardial infarction
8. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
9. The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project
10. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial
11. The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function – A systematic review
12. P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis
13. Transcriptional regulation of vascular smooth muscle cell proliferation, differentiation and senescence: Novel targets for therapy
14. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time
15. Exercise-induced pulmonary hypertension in HFpEF and HFrEF: Different pathophysiologic mechanism behind similar functional impairment
16. Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy
17. Eighty years of oral anticoagulation: Learning from history
18. ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry
19. Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status
20. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis
21. Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI
22. Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis
23. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
24. Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status
25. Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins – Confirmation from PCSK9 Inhibitor Studies
26. Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease
27. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score
28. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation
29. Usefulness of Triiodothyronine Replacement Therapy in Patients With ST Elevation Myocardial Infarction and Borderline/Reduced Triiodothyronine Levels (from the THIRST Study)
30. Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy
31. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study)
32. Empagliflozin restores autophagy and attenuates ponatinib-induced cardiomyocyte senescence and death
33. Chronic thromboembolic disease: Association with exercise-induced pulmonary hypertension and right ventricle deterioration
34. Interindividual Variability in Biomarkers of Cardiometabolic Health after Consumption of Major Plant-Food Bioactive Compounds and the Determinants Involved
35. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis
36. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
37. Right heart-pulmonary circulation unit and cardiac resynchronization therapy
38. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation
39. The value of imaging in subclinical coronary artery disease
40. Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges
41. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
42. Self-expanding stent for complex percutaneous coronary interventions: A real life experience
43. Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study)
44. Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromes—The COPACS Study
45. Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?
46. Epigenetic regulation of insulin-like growth factor signaling: A novel insight into the pathophysiology of neonatal pulmonary hypertension
47. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials
48. Circulating endothelial progenitor cells: Do they live up to their name?
49. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia
50. D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.